Location: United States
Total raised: $61M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.10.2025 | Series B | $40M | Sonder Cap... |
| 15.08.2024 | - | $21M | - |
Mentions in press and media 6
| Date | Title | Description |
| 14.10.2025 | Jupiter Endovascular Secures Over $40M, Advances Revolutionary Catheter Technology | Jupiter Endovascular secured over $40M in Series B funding. This capital fuels development and commercialization of its TFX catheter platform. This innovative system brings unprecedented stability and control to complex endovascular procedu... |
| 08.10.2025 | Jupiter Endovascular exceeds $40M series B fundraising target for its TFX platform | Jupiter Endovascular, which is a startup spun out of Neptune Medical a year ago, raised more than its target of $40 million in series B fundraising it plans to use to further develop and launch its TFX catheter platform. The platform, which... |
| 07.10.2025 | Jupiter Endovascular Closes Over $40M Series B Funding | Jupiter Endovascular, a Menlo Park, CA-based medical technology startup, closed its Series B funding at over $40M. The amount of the deal was not disclosed. The round was led by Sonder Capital, with participation from Senvest Management, LB... |
| 16.08.2024 | GI robotics developer Neptune Medical raises $97M, launches Jupiter Endovascular | The gastrointestinal device and robotics developer Neptune Medical announced it has raised $97 million in venture capital funds—and that it’s launched another subsidiary into its orbit. Jupiter Endovascular aims to improve the precision and... |
| 15.08.2024 | Jupiter Endovascular Raises $21M in Funding | Jupiter Endovascular, Inc., a Menlo Park, CA-based medical technology startup, exited stealth mode with a $21M new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic inv... |
| - | Jupiter Endovascular | “Our vision spans the breadth of cardiovascular disease where we see compelling opportunities to reimagine therapies for millions of patients.” |